Results of the PROPINE randomized controlled trial: determining the ever-elusive target, the optimal plan for relapses of nephrotic syndrome in children

John D Mahan; Mahmoud Kallash; William E Smoyer

doi:10.1016/j.kint.2020.10.034

Results of the PROPINE randomized controlled trial: determining the ever-elusive target, the optimal plan for relapses of nephrotic syndrome in children

Kidney Int. 2021 Feb;99(2):311-313. doi: 10.1016/j.kint.2020.10.034.

Authors

John D Mahan¹, Mahmoud Kallash², William E Smoyer³

Affiliations

¹ Department of Pediatrics, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA. Electronic address: [email protected].
² Department of Pediatrics, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
³ Department of Pediatrics, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA; Center for Clinical and Translational Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.

PMID: 33509352
DOI: 10.1016/j.kint.2020.10.034

Abstract

Best treatments for initial presentation and relapses in children with nephrotic syndrome (NS) are still to be defined. The PROPINE study, published in this issue of Kidney International, demonstrates for relapse of childhood NS, the non-inferiority of a short taper (over 36 days) after remission with steroids. This study reinforces the need for more well-designed studies and the incorporation of predictive biomarkers, genetic studies, and other details to personalize treatment for each child with idiopathic NS.

Keywords: glomerular disease; nephrotic syndrome; pediatric nephrology.

Publication types

Comment

MeSH terms

Child
Epinephrine / analogs & derivatives
Humans
Nephrotic Syndrome* / diagnosis
Nephrotic Syndrome* / drug therapy
Prednisone
Recurrence

Substances

dipivefrin
Prednisone
Epinephrine